Attenuation of neutrophil driven inflammation and fungal growth by pilocarpine hydrochloride
This study demonstrates that pilocarpine hydrochloride offers a dual therapeutic benefit for fungal infections by simultaneously inhibiting the growth of various fungal species and attenuating neutrophil-driven inflammation through the induction of apoptosis and suppression of activation, thereby reducing immune-mediated tissue damage.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human body is a fortress constantly under siege by microscopic invaders, and its first line of defense is a specialized army of white blood cells called neutrophils. These cells rush to the site of an infection, such as a fungal invasion on the eye, to engulf and destroy the threat. However, this defense mechanism is a double-edged sword. While the neutrophils work to clear the fungus, their aggressive activity can damage the surrounding healthy tissue, leading to scarring and permanent vision loss in conditions like fungal keratitis. The challenge for modern medicine has been to find a way to stop the infection without triggering this destructive immune overreaction. Current treatments focus solely on killing the fungus, leaving the body's own inflammatory response unchecked and often harmful to the patient's long-term health.
Researchers at the University of Edinburgh have investigated a potential solution using a drug already familiar to doctors: pilocarpine hydrochloride. This medication is commonly used to treat non-infectious eye conditions like glaucoma by shrinking the pupil. The team discovered that this drug possesses a unique dual capability: it can slow down the growth of fungi while simultaneously calming the immune system's most aggressive soldiers. By testing the drug in laboratory settings, they found that pilocarpine does not just stop the fungus from spreading; it also signals the neutrophils to stand down, undergo a natural form of cell death, and stop releasing the toxic substances that cause tissue damage. This suggests that the drug could be repurposed to treat fungal eye infections by attacking the pathogen and protecting the host tissue at the same time.
The study began by examining how pilocarpine affects different types of fungi known to cause eye infections, including Candida albicans, Aspergillus flavus, and Fusarium keratoplasticum. In the lab, the researchers exposed these fungi to varying concentrations of the drug. They observed that as the amount of pilocarpine increased, the fungi's ability to grow and produce energy dropped significantly. The drug was particularly effective at stopping the fungi from changing shape. Many dangerous fungi, like Candida, can switch from a simple yeast form into long, thread-like structures called hyphae, which allow them to burrow into tissue and form protective biofilms. Pilocarpine prevented this transformation, keeping the fungi in a less dangerous state and reducing their overall biomass. This effect was consistent across all three fungal species tested, indicating that the drug targets a fundamental process in fungal metabolism rather than just one specific species.
Next, the team turned their attention to the human immune response. They isolated neutrophils from the blood of healthy volunteers and exposed them to the drug to see how the cells reacted. The results were striking. At higher concentrations, pilocarpine prompted the neutrophils to enter a state of programmed cell death, known as apoptosis. This is a crucial distinction because apoptosis is a quiet, orderly way for cells to die that does not trigger further inflammation, unlike the chaotic death of cells that are simply crushed or poisoned. By encouraging the neutrophils to die peacefully, the drug effectively reduced the number of active soldiers at the infection site, thereby limiting the potential for collateral damage to the eye tissue.
The researchers then looked at how the drug influenced the behavior of the neutrophils that were still alive. Normally, when these cells detect an infection, they become activated, change their shape to move toward the threat, and release powerful weapons like reactive oxygen species and enzymes to kill the invader. The study showed that pilocarpine blocked these actions. The treated neutrophils failed to change their shape effectively and lost their ability to migrate toward chemical signals that usually guide them to an infection. Furthermore, the drug significantly reduced the production of reactive oxygen species and the release of enzymes that are typically used to destroy pathogens. Even the formation of neutrophil extracellular traps—nets of DNA and proteins that cells throw out to catch and kill fungi—was dampened when the drug was present, particularly when the immune response was driven by chemical signals rather than direct contact with dead fungal parts.
To see if these effects held up in a more realistic environment, the scientists created a three-dimensional model of a human cornea infected with fungus. They built a tiny chamber filled with a collagen matrix that mimicked the structure of the eye's stroma, the middle layer of the cornea. They introduced the fungus to one side and neutrophils to the other, allowing the immune cells to migrate toward the infection. In the untreated models, the fungus grew aggressively into the tissue, and a large number of neutrophils rushed in, creating a chaotic scene of infection and inflammation. In the models treated with pilocarpine, the fungal growth was visibly restrained, and far fewer neutrophils migrated into the tissue. The drug successfully created a scenario where the infection was contained, and the immune system did not overreact, effectively protecting the structural integrity of the corneal model.
However, the researchers also noted a potential complication. While the drug was effective against the fungus and the immune response, it did cause some changes in the corneal cells themselves, leading to cell death in the tissue model at high concentrations. This suggests that while the drug shows great promise for reducing inflammation and fungal growth, its use would need to be carefully balanced to avoid harming the eye's own cells. The study concludes that pilocarpine hydrochloride offers a novel approach to treating fungal infections by acting on two fronts: it hinders the fungus's ability to grow and spread while simultaneously calming the immune system's destructive tendencies. This dual action could provide a new therapeutic strategy for conditions like fungal keratitis, where the goal is to clear the infection without sacrificing vision to the body's own defense mechanisms.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.